MEGA Array Family and Next-Generation
Sequencing to Support Comprehensive Genomics Approach toward
Personalized Medicine
Illumina, Inc. (NASDAQ: ILMN) today announced it has signed four
separate biobanking deals with Vanderbilt University, University of
Colorado at Denver, Partners HealthCare, and Montreal Heart
Institute to advance personalized medicine and improve health care.
Under the agreements, the large sample collections housed at each
institution will be genotyped using Illumina technologies. By
combining genomic information with electronic medical records and
clinical information, the institutions hope to accelerate
discoveries that will improve human health.
The Infinium® Expanded Multi-Ethnic Genotyping Array, Infinium
HumanMethylation 450K Array and Illumina sequencing systems will be
used to analyze an initial 200,000 samples and gain insight into
the underlying genetic factors that may contribute to heart
disease, cancer, Alzheimer’s, bipolar disorder, and Crohn’s
disease, among many other complex diseases.
“These four personalized medicine programs represent progressive
examples of how characterizing the genome using multiple genetic
analysis solutions is significantly advancing the understanding of
human biology. These programs are at the forefront of translational
research and the clinical application of genomic data,” said
Illumina Executive Vice President and Chief Commercial Officer,
Christian Henry.
Vanderbilt University
As part of Vanderbilt University’s early commitment to support
the Precision Medicine Initiative, Dr. Nancy Cox will lead its
trans-institution genetic efforts by combining Vanderbilt’s
national leadership in DNA biobanking, biomedical informatics and
pharmacogenomics data. The genetic analysis of data from 100,000
samples will provide valuable insights to genetic factors in human
disease with the goal of improving health care.
“Our BioVU biobank is at the core of a vision that will combine
genome variation, biomarker data, patient electronic medical record
(EMR) information and pharmacogenomic data to advance personalized
medicine,” said Vanderbilt University Genetics Institute and
Division of Genetic Medicine Director, Nancy Cox, PhD. “We are
pleased to partner with Illumina and will utilize their MEGA EX
genotyping array and DNA sequencing to examine how genome variation
that has been shown to impact gene expression across a variety of
tissues alters risk of common diseases. The opportunity for
partnerships in this discovery space were key in our decision to
work with them.”
University of Colorado at Denver
The University of Colorado Anschutz Medical Campus has launched
a new personalized medicine initiative focused on integrating
information from electronic medical records data with molecular
data, genetic mapping, and basic biology to redefine disease and
health, and fundamentally change the way medicine is practiced.
This new program will be led by Kathleen Barnes, PhD, head of the
Division of Biomedical Informatics and Personalized Medicine in the
Department of Medicine.
Under this initiative Dr. Barnes and her team will initially
genotype 30,000 samples on the Illumina MEGA EX BeadChip with
analysis of 2,000 samples on the new DNA Methylation EPIC chip.
Upon successful completion of this pilot study, and ongoing patient
sample collection, this new biobank anticipates analyzing hundreds
of thousands of samples per year over the next several years.
Partners HealthCare Biobank
The Partners HealthCare Biobank is part of Partners HealthCare
Personalized Medicine, a center devoted to enhancing the adoption
of genomic technologies to improve patient care across the Partners
Health System including Massachusetts General Hospital and Brigham
and Women’s Hospital. The Biobank is a resource that provides
access to high-quality samples to help foster research, to further
understanding of the causes of common diseases, and advance
the practice of personalized medicine. Partners HealthCare is
currently engaged in analyzing 25,000 samples using Illumina
technology to perform RNA sequencing, DNA Methylation array and
MEGA Array.
“We have chosen Illumina array and sequencing products to be the
platform for the Partners Biobank because of Illumina’s
demonstrated capability in this field,” said Dr. Scott Weiss,
Director at Partners Personalized Medicine, Partners HealthCare and
Professor of Medicine at Harvard Medical School. “This new
partnership with Illumina will make this data available to our
entire faculty, supporting our research efforts as we work to
discover new ways to improve the lives of our patients.”
Montreal Heart Institute
The Montreal Heart Institute will use Illumina’s MEGA array to
genotype over 50,000 samples from their biobank as part of an
overall effort to identify genetic predictors of drug response in
cardiometabolic diseases. A subset of these samples will be used in
a longitudinal cohort study as the final clinical validation
study.
“We have chosen to use Illumina array products with our biobank
samples which we believe will provide good genome-wide coverage for
a number of ethnic populations and valuable information from rare
variants and enriched content,” said the Director of Beaulieu
Saucier Pharmacogenomics Centre at the Montreal Heart Institute,
Dr. Marie-Pierre Dube.
The genotyping programs for Partners HealthCare Biobank,
Montreal Heart Institute, and Vanderbilt University are currently
underway. University of Colorado at Denver will start genotyping Q1
2016.
About Illumina, Inc.
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture and other emerging segments. To
learn more, visit www.illumina.com and follow
@illumina.
Forward-Looking Statements
This release may contain forward-looking statements that involve
risks and uncertainties. Important factors that could cause actual
results to differ materially from those in any forward-looking
statements are detailed in our filings with the Securities and
Exchange Commission, including our most recent filings on Forms
10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date
of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160201005047/en/
Illumina, Inc.Investors:Rebecca
Chambers858-255-5243rchambers@illumina.comorMedia:Mina
Nicoletti858-882-6822pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024